Inside the Structural Reforms That Made IU Indianapolis a Translational Overachiever
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
Every university on this list represents the highest tier of U.S. biomedical research. We ranked 243 research universities across the United States on their ability to translate scientific discovery into real-world healthcare solutions, evaluated on 25 indicators across three core domains.
The University of Louisiana at Lafayette ranks 231st among universities in the Cure Innovation Index. Located in Lafayette, Louisiana, the institution shows developing capacity across all three measured domains.
Learn More
The University of Idaho ranks 232nd among 243 universities in the Cure Innovation Index, located in Moscow, Idaho. Idaho's land-grant institution, it conducts biomedical research in a predominantly rural setting.
Learn More
Miami University, a public university in Oxford, Ohio, ranks 233rd among the 243 universities in the Cure Innovation Index. Research capabilities and market translation place at comparable levels within the tier; entrepreneurial readiness, at 189th, is the institution's strongest domain.
Learn More
Nova Southeastern University ranks 234th among universities in the Cure Innovation Index, located in Fort Lauderdale, Florida. Its relative strength is in market translation, where it outpaces its standings in both research capabilities and entrepreneurial readiness, each of which fall in the lower range among ranked universities.
Learn More
Jackson State University ranks 235th among 243 universities in the Cure Innovation Index. Located in Jackson, Mississippi, it is a historically Black university with a mission centered on serving underrepresented communities across the U.S. South.
Learn More
Wichita State University ranks 236th among universities in the Cure Innovation Index, based in Wichita, Kansas. Research capabilities and market translation perform at similar levels, both within the lower tier of ranked universities, while entrepreneurial readiness emerges as a relative strength within the institution's profile.
Learn More
The University of Alaska, Fairbanks ranks 237th among the 243 universities in the Cure Innovation Index. Situated in interior Alaska, the university places in the lower tier across Research Capabilities and Market Translation, with both domains reflecting a broadly similar standing.
Learn More
Charles R. Drew University of Medicine and Science ranks 238th among the 243 universities in the Cure Innovation Index and is based in Los Angeles, California.
Learn More
Queens College (CUNY), located in New York, New York, ranks 239th among 243 universities in the Cure Innovation Index. The university places toward the lower end of the rankings in both research capabilities and market translation, while its entrepreneurial readiness standing is comparatively stronger.
Learn More
The University of Alabama at Tuscaloosa ranks 240th in the Cure Innovation Index among the 243 universities evaluated. Located in Tuscaloosa, Alabama, the university shows its relative strength in Entrepreneurial Readiness, where it stands above its overall rank, supported by an incubator and accelerator program.
Learn More

From a pool of more than 6,000 institutions, the top 303 were ranked using two dozen indicators — from scientific foundation and lab infrastructure to patents, products, and partnerships — drawn from more than a dozen federal and commercial databases, an original audit of all institutions, and surveys of more than 3,300+ scientists, industry leaders, and biomedical experts.
Innovation isn't a single moment — it's an entire ecosystem. The Index evaluates institutions across two dozen indicators, grouped in three core domains that reveal the full picture of what it takes to turn groundbreaking science into real-world impact.
How a resource-constrained university built a top-15 translation engine — and what other institutions can learn from it.
With 27 institutions ranked among the country’s top biomedical innovators, New York’s research cluster spans the entire state, and outperforms nearly every other in the country.

As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.
The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.
